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Glucagon and glucagon-like peptide (GLP)-1 are the primary
products of proglucagon processing from the pancreas and gut,
respectively. Giving dual agonists with glucagon and GLP-1
activity to diabetic, obese mice causes enhanced weight loss
and improves glucose tolerance by reduction of food intake and
by increase in energy expenditure (EE). We aimed to observe the
effect of a combination of glucagon and GLP-1 on resting EE and
glycemia in healthy human volunteers. In a randomized, double-
blinded crossover study, 10 overweight or obese volunteers
without diabetes received placebo infusion, GLP-1 alone, glucagon
alone, and GLP-1 plus glucagon simultaneously. Resting EE—
measured using indirect calorimetry—was not affected by GLP-1
infusion but rose signiﬁcantly with glucagon alone and to a similar
degree with glucagon and GLP-1 together. Glucagon infusion was
accompanied by a rise in plasma glucose levels, but addition of
GLP-1 to glucagon rapidly reduced this excursion, due to a syner-
gistic insulinotropic effect. The data indicate that drugs with
glucagon and GLP-1 agonist activity may represent a useful treat-
ment for type 2 diabetes and obesity. Long-term studies are
required to demonstrate that this combination will reduce weight
and improve glycemia in patients. Diabetes 62:1131–1138, 2013
Glucagon and glucagon-like peptide (GLP)-1 are,respectively, pancreatic and intestinal hor-mones derived from the same proglucagonpeptide but with divergent roles in metabolism.
Glucagon has primarily been characterized as a counter-
regulatory hormone that responds to hypoglycemia and
fasting by stimulating glycogenolysis and gluconeogenesis,
as well as hepatic fatty acid b-oxidation and ketogenesis
(1). Glucagon is an integral part of the body’s neurohor-
monal response to stress together with cortisol and cat-
echolamines (2). On the other hand, GLP-1 is released
postprandially and has primary roles in enhancing the
b-cell insulin response to eating, enhancing b-cell survival,
inhibiting gastric emptying, and suppressing appetite (3). A
third proglucagon derivative, oxyntomodulin, possesses
both glucagon receptor (GcgR) and GLP-1 receptor (GLP-
1R) agonist activity (4,5) and is also released from the gut
postprandially.
GLP-1 and its analogs are used for their insulinotropic
actions as therapies for type 2 diabetes. As GLP-1 sup-
presses appetite (6), patients generally experience weight
loss with GLP-1 analog therapy (3). However, the magni-
tude of weight loss is restricted by dose-limiting nausea
and vomiting (7), as well as by the fact that GLP-1 tends to
reduce energy expenditure (EE) (8). In this connection,
glucagon has emerged as a suitable therapeutic partner for
GLP-1. Glucagon is also known to reduce appetite (9) but
in addition increases EE (10). The combination of GLP-1
and glucagon therefore makes an attractive proposition for
obesity therapy. Consistent with this hypothesis, the weak
GcgR/GLP-1R coagonist oxyntomodulin is known to sup-
press appetite (11) and to increase EE, causing consider-
able weight loss in obese volunteers (12,13).
The hyperglycemic effect of glucagon has deterred in-
vestigation of its potential as an obesity treatment. How-
ever, oxyntomodulin and other GcgR/GLP-1R coagonists
have been shown to have neutral or beneﬁcial glycemic
effects in rodents with diet-induced obesity (14–16). This
has been hypothesized by others to be due to one or more
mechanisms: 1) intrinsic GLP-1R agonism having an effect
opposing and neutralizing that mediated by GcgR stimu-
lation, 2) the metabolic beneﬁts of body weight loss out-
weighing any diabetogenic effect of GcgR stimulation, and
3) an unexpectedly beneﬁcial metabolic effect of sustained
GcgR stimulation (15).
These observations suggest that combined administra-
tion of GcgR and GLP-1R agonists, or of a single coagonist,
could be useful to treat type 2 diabetes and obesity.
However, the separate and combined effects of GLP-1 and
glucagon on EE and glycemia have not previously been
demonstrated in humans. We therefore decided to in-
vestigate the effects of the GLP-1 and glucagon combina-
tion in healthy human volunteers. Speciﬁcally, we wished
to conﬁrm that glucagon increases resting EE and that this
effect is retained when GLP-1 is combined with glucagon.
Secondly, we wished to conﬁrm that GLP-1 is able to
ameliorate the hyperglycemia induced by glucagon.
RESEARCH DESIGN AND METHODS
The study was approved by the Hammersmith and Queen Charlotte’s Research
Ethics Committee (09/H0707/76) and carried out according to the principles of
the Declaration of Helsinki. Ten overweight/obese volunteers were recruited
by advertisement (Table 1). Potential participants were screened and de-
termined to be healthy by medical history, physical examination, hematolog-
ical and biochemical testing, and 12-lead electrocardiogram. All female
participants were premenopausal and had regular menstrual cycles. None
were taking the combined oral contraceptive pill, but one volunteer was taking
a progestogen contraceptive pill that was deemed acceptable, as progestogen-
based contraception has previously been found not to alter EE (17).
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Volunteers were placed brieﬂy under a calorimeter canopy to conﬁrm that
they would be comfortable in it during study visits.
Volunteers attended for ﬁve consecutive study visits spaced $2 days apart.
The initial visit was an unblinded “dummy” visit where gelofusine (B. Braun,
Crawley, U.K.) was infused to acclimatize volunteers to study procedures. For
avoidance of liver glycogen depletion, volunteers were asked to avoid alcohol
and strenuous exercise for 24 h prior to each study visit and were given a high-
energy snack (each containing 3.8 g fat, 20.4 g carbohydrate, and 1.9 g protein;
Alpen, Weetabix, U.K.) to consume at 2200 h the night before the study. They
arrived at the clinical research facility at 0830 h having eaten a small, low-fat
breakfast of two McVitie’s Rich Tea biscuits (each containing 1.3 g fat, 5.9 g
carbohydrate, and 0.6 g protein; United Biscuits) at 0700 h. Upon arrival,
volunteers were asked to empty their bladder; urine was collected at the end
of each study visit to provide an estimate of urinary nitrogen excretion.
After dual cannulation to provide a blood sampling point and to allow in-
travenous infusion of hormones, volunteers were asked to swallow a core
temperature measurement capsule (Equivital; Hidalgo, Swavesey, U.K.). They
were placed under the indirect calorimeter canopy (Gas Exchange Monitor;
GEM Nutrition, Daresbury, U.K.) at 0 min (0900 h). Before each measurement,
the calorimeter was calibrated with “zero” (0.00% O2 and 0.00% CO2) and
“span” (20.00% O2, 1.00% CO2) gases (BOC Gases, Surrey, U.K.). Volunteers lay
semirecumbent on a bed and were allowed to watch television or listen to
music. Calorimeter measurements were allowed to stabilize during the ﬁrst 30
min. Resting EE, respiratory quotient (RQ), and carbohydrate and fat oxida-
tion rates were estimated from measurements of VO2 and VCO2 recorded each
minute, with adjustment for urinary nitrogen excretion. Protein oxidation rate
over the entire study visit was estimated from urinary nitrogen excretion
(18,19). Baseline resting EE was deﬁned as the mean of measurements taken
during the ﬁnal 15 min of this 45-min baseline phase.
At 45 min, a hormone infusion was started, which lasted for 45 min. Vol-
unteers received intravenous infusions of placebo (gelofusine), glucagon (50
ng/kg/min; Novo Nordisk, Crawley, U.K.), GLP-17–36amide (0.8 pmol/kg/min;
Clinalfa Basic, Bachem, Switzerland), or combined GLP-1 and glucagon at the
above-mentioned doses, with infusion allocation determined in a four-way,
randomized design. Gelofusine was used as the vehicle for hormone infusions
in order to minimize absorption of peptides to infusion lines and syringes (20).
The infusion was “ramped” to establish stable plasma hormone levels rapidly,
with an infusion rate four times the nominal rate for the initial 5 min reduced
to twice the nominal rate for the next 5 min and then to the nominal rate for
the remaining 35 min. The dose of glucagon was selected after a dose-ﬁnding
study to determine a well-tolerated dose of glucagon with consistent effects on
EE.
Calorimetry continued during the 45-min infusion. As with the baseline
phase, calorimetry measurements were allowed to stabilize for 30 min before
measurements from the ﬁnal 15 min were used to calculate the infusion-phase
resting EE, RQ, and substrate oxidation rates. At 90 min, the infusion and
calorimetry were stopped. Each study visit was terminated at 105 min.
Blood samples were collected at 30, 45, 60, 75, 90, and 105 min and assayed
for insulin, glucose, nonesteriﬁed fatty acids (NEFAs), thyroid hormones,
cortisol, GLP-1, glucagon, and total/acyl ghrelin levels. Samples for analysis of
plasma GLP-1 and glucagon were collected in lithium heparin tubes with 100 mL
aprotinin (1,000 kallikrein inhibitor units) and were measured using estab-
lished radioimmunoassays (21,22). NEFAs were measured by the Department
of Chemical Pathology, Great Ormond Street Hospital National Health Service
Trust. Ghrelin was measured using total ghrelin and active (acyl) ghrelin
ELISA assays (Millipore, Watford, U.K.). Other analytes were measured by the
Department of Chemical Pathology, Imperial College Healthcare National
Health Service Trust.
Statistical analysis was carried out, as noted in the text and Figure captions,
using GraphPad Prism 5.0d (GraphPad Software, San Diego, CA) and STATA 12
(StataCorp, College Station, TX). The change from baseline in the calorimetric
data was modeled using a linear mixed model with random intercepts to model
patient heterogeneity. This model allowed the assessment of the presence of
a period effect or a period-by-treatment interaction. The within-subject com-
parison was based on the treatment effect as long as there was not a signiﬁcant
period-by-treatment interaction. In addition, the baseline calorimetric data and
patient weight were included in the model to estimate the adjusted treatment
effect. Two-way repeated-measures ANOVA with Bonferroni post hoc test was
used to compare differences in glucose, insulin, and ghrelin levels. Area under
the curve was calculated using the trapezoidal rule, and differences were
compared using one-way repeated-measures ANOVA with Tukey post hoc test.
Plasma NEFA concentrations were analyzed with one-way repeated-measures
ANOVA and Bonferroni post hoc test. Substrate oxidation rates were analyzed
using one-way repeated-measures ANOVA. Unless otherwise noted, results are
presented as means 6 SEM. Statistical signiﬁcance was deﬁned as P , 0.05.
RESULTS
Mean plasma levels of GLP-1 at 30 min before the start of
the infusion were 15–23 pmol/L. In those arms receiving
the infusion of GLP-1 at 0.8 pmol/kg/min, GLP-1 levels rose
to 90–103 pmol/L 60 min after initiation (Fig. 1A). Similarly,
glucagon levels at 30 min before starting were 8–11 pmol/L.
In those arms receiving the infusion of glucagon at 50
ng/kg/min, glucagon levels rose to 239–260 pmol/L (Fig.
1B). After the infusion was stopped at 90 min, glucagon
and GLP-1 levels also rapidly fell to baseline. No adverse
events were recorded with the hormone infusions.
GLP-1 infusion was accompanied by a slight decline in
plasma glucose levels from 5.3 6 0.1 to 4.1 6 0.1 mmol/L
as expected (Fig. 2A). Glucagon infusion, conversely, in-
duced a rise in plasma glucose to a peak of 8.3 6 0.4
mmol/L at 75 min. This rise was blunted when GLP-1 and
glucagon were combined, with a peak of 7.1 6 0.5 mmol/L
at 75 min, declining to 6.2 6 0.7 mmol/L at the end of the
infusion at 90 min (Fig. 2A).
Consistent with its glucose-dependent insulinotropic
effect, GLP-1 induced an early, small rise in insulin levels
from 8.1 6 2.2 to 22.0 6 4.1 mU/L, which fell back to
baseline at later time points (Fig. 2C). Glucagon infusion
caused a more marked rise in insulin to a peak of 56.2 6
10.2 mU/L at 90 min. The combination of GLP-1 and glu-
cagon caused a synergistic rise in insulin levels to a peak
of 135.6 6 35.7 mU/L—a sixfold rise compared with GLP-1
alone and a 2.4-fold rise compared with glucagon alone
(Fig. 2C).
Infusion of glucagon caused a sharp drop in NEFA levels
from 0.46 6 0.07 to 0.18 6 0.03 mmol/L (Fig. 3). Similarly,
the GLP-1 plus glucagon combination caused a fall in
NEFA levels from 0.38 6 0.06 to 0.13 6 0.18 mmol/L. No
signiﬁcant change in NEFA levels was seen in the placebo
or GLP-1 arms.
Baseline resting EE was not signiﬁcantly different be-
tween infusion arms. A linear mixed model analysis of
repeated measurements, taking into account subject
weight, baseline measurements, and the order of infusion
(period by treatment), was used to analyze the differences
in resting EE induced by the different infusions: no sig-
niﬁcant interactions were found with these three possible
confounding factors (Fig. 4A and Table 2). There was no
signiﬁcant change in resting EE during GLP-1 infusion.
However, resting EE increased signiﬁcantly during gluca-
gon infusion by a mean of 146.99 kcal/day. This effect
was retained when GLP-1 and glucagon were infused in
TABLE 1
Demographic details of volunteers in the study
Volunteer
Height
(m)
Weight
(kg)
BMI
(kg/m2)
Age
(years) Sex
G02 1.66 99.1 36.0 26 F
G03 1.63 80.0 30.1 28 F
G04 1.78 101.5 32.0 31 M
G05 1.94 96.4 25.6 23 M
G06 1.81 99.0 30.2 49 M
G07 1.84 89.1 26.3 48 M
G08 1.87 100.3 28.7 32 M
G09 1.82 91.1 27.5 32 M
G10 1.71 77.2 26.4 44 F
G11 1.61 79.1 29.8 45 M
Mean 1.77 91.3 29.3 25.8 7 M/3 F
F, female; M, male.
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combination, with a mean increase in resting EE of 146.26
kcal/day.
Baseline RQ values were again not signiﬁcantly different
between infusion arms. The changes in RQ upon infusion
were analyzed using the linear mixed model (Fig. 4B and
Table 2). There was no signiﬁcant change in RQ for the
GLP-1 infusion arm. There was a signiﬁcant increase in RQ
in the glucagon arm as well as in the GLP-1 plus glucagon
arm.
Substrate oxidation rates are summarized in Table 3,
which shows that there were no signiﬁcant differences
comparing all arms of the study at baseline. Carbohydrate
and fat oxidation rates were analyzed using the linear
mixed model (Fig. 4C and D and Table 2). There was no
signiﬁcant change in carbohydrate oxidation rates with
GLP-1 infusion. There was a signiﬁcantly increased
carbohydrate oxidation rate with glucagon infusion and
a similar increase with GLP-1 plus glucagon infusion.
There was no signiﬁcant change in fat oxidation rate either
with GLP-1 infusion or with glucagon infusion, whereas
the combined GLP-1 plus glucagon infusion signiﬁcantly
decreased fat oxidation rates.
There was no signiﬁcant variation in thyroid hormone
levels between the baseline phase and the infusion phase
apart from a small, statistically signiﬁcant reduction in thy-
rotropin levels when volunteers were given glucagon, which
was not seen in the GLP-1 plus glucagon arm and which is
therefore of uncertain biological signiﬁcance (data not
shown). There was no signiﬁcant difference in core tem-
perature (data not shown). There were no signiﬁcant
changes in systolic and diastolic blood pressure, although
there was a trend toward a higher pulse rate in the glucagon
FIG. 1. Plasma GLP-1 (A) and glucagon (B) levels after hormone infusion. Mean 6 SEM plasma venous levels plotted. Duration of infusion from 45
to 90 min denoted by gray bar.
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and GLP-1 plus glucagon infusion arms compared with the
placebo and GLP-1 infusion arms (data not shown).
Ghrelin is a key appetite-regulatory hormone that
increases food intake (23). Acyl ghrelin, incorporating an
octanoyl group linked to the Ser3 residue, is the active
form of ghrelin that activates its growth hormone secre-
tagogue receptor 1a (24). As glucagon and GLP-1 have
been known to suppress appetite (6,25) and ghrelin se-
cretion (26,27), the plasma levels of ghrelin during infusion
were examined (Fig. 5). Infusion of GLP-1 alone did not
inﬂuence circulating total and acyl ghrelin levels. Gluca-
gon infusion alone reduced total and acyl ghrelin but not to
a statistically signiﬁcant degree. By contrast, the combi-
nation of GLP-1 and glucagon signiﬁcantly reduced total
and acyl ghrelin.
DISCUSSION
In this clinical study, we have veriﬁed for the ﬁrst time
that combined infusion of GLP-1 and glucagon increases
resting EE acutely, by the equivalent of ~150 kcal/day, in
a manner similar to that of glucagon infusion alone. We
speculate that this phenomenon could be mediated by
increased thermogenesis in brown adipose tissue (28)
and by futile substrate cycling (29). These effects may be
triggered directly by glucagon acting on tissue GcgR (e.g.,
in brown adipose tissue) or indirectly via an increase in
catecholamines (2). No consistent effects of glucagon or
GLP-1 plus glucagon were seen on the thyroid hormone
axis or on cortisol secretion (data not shown). One caveat
is that our observations on EE relate to the acute effects
of the GLP-1 plus glucagon combination; a longer-term
study will be required to conﬁrm that chronic GLP-1R/
GcgR agonism in humans leads to a sustained elevation of
EE, as was seen in diet-induced obesity rodent models
(15). If such an elevation of EE were to be sustained, it
would represent ;7.5% of the typical 2,000 kcal/day
resting EE of a 40-year-old male of 100 kg in weight and
1.75 m in height.
FIG. 2. Effects of glucagon, GLP-1, and GLP-1 plus glucagon infusion on glucose (A and B) and insulin (C and D) levels. A and C: Mean 6 SEM
venous plasma glucose and serum insulin levels plotted. Duration of infusion from 45 to 90 min denoted by gray bar. *P< 0.05, ***P< 0.001, ****P<
0.0001 compared with placebo. B: Area under the glucose curve 6SEM plotted. Signiﬁcantly different area under the curve values are indicated
as follows: ##P < 0.01, ###P < 0.001 compared with placebo; †P < 0.05 compared with glucagon. D: Area under the insulin curve 6SEM plotted.
Signiﬁcantly different area under the curve values are indicated as follows: $P< 0.05, $$$P< 0.001 compared with placebo; %%P< 0.01 compared
with glucagon.
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At the dose used, glucagon provokes an acute rise in
plasma glucose levels, probably via glycogen breakdown.
Hyperglycemia is an expected effect of glucagon. Indeed,
glucagon antagonists have been mooted as treatments for
diabetes on the basis that sustained hyperglucagonemia
contributes to the pathogenesis of diabetes (1), although
there are major concerns that this strategy may promote
hepatic steatosis and liver injury (30). We found that
coinfusion of GLP-1 blunted the hyperglycemic effect of
glucagon via a synergistic insulinotropic effect, although it
did not completely neutralize the acute rise in glucose. It
remains possible that the acute hyperglycemic effect
would resolve with continued combination treatment, due
to increased insulin release and exhaustion of liver gly-
cogen stores. Indeed, the initial hyperglycemia did resolve
toward the end of the 45-min infusion of GLP-1 plus
glucagon—unlike with glucagon alone (Fig. 2A). It is also
noteworthy that oxyntomodulin, administered for 4 weeks
to human volunteers, did not result in hyperglycemia (13).
Our study used overweight-obese healthy volunteers
without diabetes. Would the synergistic insulinotropic ef-
fect of the GLP-1 and glucagon combination be seen in
patients with type 2 diabetes and decreased b-cell reserve?
Despite the fact that such patients exhibit decreased sen-
sitivity to incretins at physiological levels, it is notable that
GLP-1 at pharmacological levels is still able to stimulate
a signiﬁcant insulin response (31). Early indications from
clinical trials also suggest that long-term GLP-1R agonist
therapy carries positive beneﬁts for insulin secretion and
FIG. 3. Effects of glucagon, GLP-1, and GLP-1 plus glucagon infusion on
NEFA levels. Means 6 SEM plotted for NEFA levels during the baseline
phase (30 min) and at the end of the infusion phase (90 min). ***P <
0.001 for difference between baseline and infusion phase values.
FIG. 4. Effects of infusions on EE. The mean changes in each parameter (695% CI) between baseline and infusion phases are plotted. Baseline
resting EEs were as follows: 1,487 6 70.9 kcal/day (placebo), 1,487 6 65.9 kcal/day (GLP-1), 1,469 6 66.0 kcal/day (glucagon), and 1,485 6 67.4
kcal/day (GLP-1 plus glucagon); they were not signiﬁcantly different (P = 0.7253, one-way repeated-measures ANOVA). Baseline RQ values for all
arms were 0.8226 0.018 (placebo), 0.8576 0.018 (GLP-1), 0.851 6 0.020 (glucagon), and 0.8346 0.022 (GLP-1 plus glucagon), and these were not
signiﬁcantly different (P = 0.5138, one-way repeated-measures ANOVA). A linear mixed-model analysis of repeated observations within subjects
was used to compare these differences for each arm. P values for the observed differences in each parameter are indicated at the top of each graph.
A: DResting EE (expressed as kilocalories per day). B: DRQ (VCO2/VO2). C: DCarbohydrate (CHO) oxidation (ox) rates (grams per minute). D: DFat
oxidation rates (grams per minute).
T.M. TAN AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 62, APRIL 2013 1135
b-cell function (32). Moreover, if chronic treatment indu-
ces enhanced weight loss, this may improve glycemia in
the long run by enhancing insulin sensitivity. Further
studies are therefore required to understand the effect of
the GLP-1 and glucagon combination when given for ex-
tended time periods and to verify that there is an overall
beneﬁcial effect on glycemia in patients with type 2 di-
abetes.
We observed that plasma NEFA concentrations fell with
glucagon and with combined GLP-1 plus glucagon infu-
sions, triggered by the insulinotropic effect of these infu-
sions. We did not observe an increase in fat oxidation rates
but, rather, observed a drop with the GLP-1 plus glucagon
combination. Although it is traditionally taught that glu-
cagon stimulates lipolysis (33), at the doses used com-
bined glucagon and GLP-1 infusions did not appear to have
any direct effect on lipolysis by adipose tissue. Indeed, it
has been shown that glucagon’s insulinotropic effect
causes a fall in NEFA levels, probably mediated by inhibition
of hormone-sensitive lipase (34,35). This ﬁnding contrasts
with results of studies by Day et al. (15), where chronic
treatment with a GLP-1R/GcgR coagonist in diet-induced
obese mice was shown to cause phosphorylation and ac-
tivation of hormone-sensitive lipase. It remains to be seen,
therefore, whether chronic GLP-1R/GcgR stimulation may
induce a lipolytic state in humans, and this should be
addressed in long-term studies of the combination.
Lastly, we show that an intravenous infusion of GLP-1
and glucagon is able to suppress the secretion of ghrelin
and that that there was a trend toward suppression of
ghrelin levels with intravenous glucagon alone. The sup-
pression of ghrelin secretion by glucagon appears to be
mediated by central mechanisms involving the hypothalamus
and pituitary and not via insulin-mediated suppression of
ghrelin secretion (26,36). We did not observe an effect of
GLP-1 alone on ghrelin secretion in our study, unlike
Hagemann et al. (27), who found that GLP-1 suppressed
ghrelin secretion. The differences may be explained by the
fact that their study used a 50% higher dose of GLP-1, and
it is notable that the suppression of ghrelin levels was
observed after a longer infusion (210–360 min), whereas
our study was curtailed after a 45-min infusion. Our data
suggest that the combination of GLP-1 and glucagon may
indirectly inﬂuence appetite by reducing the levels of the
orexigenic hormone ghrelin in addition to their respective
direct effects on appetite.
In conclusion, our observations provide initial evidence
that GLP-1R/GcgR coagonists, such as oxyntomodulin and
related hormone analogs, may be suitable to treat type
2 diabetes and obesity. However, further studies are
required to investigate whether sustained weight loss
and beneﬁcial effects on glycemia persist during chronic
treatment.
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